NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.79 +0.06 (+0.44 %)
(As of 05/25/2018 05:49 AM ET)
Previous Close$13.73
Today's Range$13.62 - $14.00
52-Week Range$2.69 - $15.80
Volume111,600 shs
Average Volume485,747 shs
Market Capitalization$725.24 million
P/E Ratio-3.77
Dividend YieldN/A
Beta2.3

About Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Debt-to-Equity RatioN/A
Current Ratio6.95
Quick Ratio6.95

Price-To-Earnings

Trailing P/E Ratio-3.77
Forward P/E Ratio-10.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.28 million
Price / Sales319.47
Cash FlowN/A
Price / CashN/A
Book Value$1.66 per share
Price / Book8.31

Profitability

EPS (Most Recent Fiscal Year)($3.66)
Net Income$-60,040,000.00
Net Margins-1,665.11%
Return on Equity-123.72%
Return on Assets-61.06%

Miscellaneous

Employees44
Outstanding Shares52,820,000

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals (NASDAQ:DRNA) issued its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.57. The biopharmaceutical company earned $1.55 million during the quarter, compared to analyst estimates of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. View Dicerna Pharmaceuticals' Earnings History.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

What price target have analysts set for DRNA?

7 analysts have issued 1 year target prices for Dicerna Pharmaceuticals' stock. Their forecasts range from $10.00 to $17.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $14.20 in the next year. View Analyst Ratings for Dicerna Pharmaceuticals.

Who are some of Dicerna Pharmaceuticals' key competitors?

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas M. Fambrough III, Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 49)
  • Mr. John B. Green CPA, Chief Financial Officer (Age 64)
  • Dr. Bob D. Brown Ph.D., Chief Scientific Officer and Sr. VP (Age 53)
  • Dr. Mark Behlke M.D., Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Prof. John J. Rossi Ph.D., Co-Founder and Chairman of Scientific Advisory Board (Age 71)

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

Media coverage about DRNA stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 48.29 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include UBS Group AG (1.16%), Artal Group S.A. (0.82%), Millennium Management LLC (0.79%), BlackRock Inc. (0.54%), Citadel Advisors LLC (0.33%) and Spark Investment Management LLC (0.28%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

Which major investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Which major investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Citadel Advisors LLC, BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., Element Capital Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $13.79.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $725.24 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (DRNA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dicerna Pharmaceuticals (NASDAQ:DRNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Dicerna Pharmaceuticals in the last 12 months. Their average twelve-month price target is $14.20, suggesting that the stock has a possible upside of 2.97%. The high price target for DRNA is $17.00 and the low price target for DRNA is $10.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.572.832.60
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.20$13.80$11.00$7.00
Price Target Upside: 2.97% upside14.62% upside21.01% upside3.18% downside

Dicerna Pharmaceuticals (NASDAQ:DRNA) Consensus Price Target History

Price Target History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ:DRNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018HC WainwrightReiterated RatingHold$14.00HighView Rating Details
4/24/2018CowenReiterated RatingBuyLowView Rating Details
4/20/2018Evercore ISIReiterated RatingOutperform$14.00 ➝ $17.00HighView Rating Details
3/28/2018B. RileyInitiated CoverageNeutral$10.00HighView Rating Details
3/9/2018Chardan CapitalInitiated CoverageNeutral ➝ NeutralHighView Rating Details
3/9/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$10.00 ➝ $17.00HighView Rating Details
2/5/2018SunTrust BanksInitiated CoverageBuy$13.00MediumView Rating Details
4/2/2017Jefferies GroupReiterated RatingBuy$8.00 ➝ $7.00LowView Rating Details
2/1/2017Leerink SwannReiterated RatingMkt PerformN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earnings History and Estimates Chart

Earnings by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.75)($0.58)($0.67)
Q2 20182($0.75)($0.29)($0.52)
Q3 20182($0.74)($0.48)($0.61)
Q4 20182($0.46)($0.40)($0.43)

Dicerna Pharmaceuticals (NASDAQ DRNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.42)N/AView Earnings Details
5/14/2018Q1 2018($0.87)($0.30)$1.75 million$1.55 millionViewListenView Earnings Details
3/8/2018Q4 2017($0.65)($0.90)$1.45 million$1.40 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.70)($0.92)$0.47 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.61)($1.15)$0.08 million$0.25 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.65)($0.68)$0.08 million$0.13 millionViewListenView Earnings Details
3/30/2017Q4 2016($0.73)($0.68)$0.13 millionViewN/AView Earnings Details
11/7/2016Q316($0.87)($0.68)$162.00 millionViewListenView Earnings Details
8/4/2016Q216($0.84)($0.75)ViewN/AView Earnings Details
5/9/2016Q116($0.86)($0.76)ViewN/AView Earnings Details
3/10/2016Q415($0.84)($0.76)$2.50 millionViewListenView Earnings Details
11/10/2015Q315($0.84)($0.82)ViewListenView Earnings Details
8/6/2015Q215($0.78)($0.86)$0.18 millionViewN/AView Earnings Details
5/11/2015Q1($0.7270)($0.79)$600.00 millionViewListenView Earnings Details
3/12/2015Q414($0.57)($0.63)$1.45 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.63)($0.63)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.42)($0.64)ViewN/AView Earnings Details
5/13/2014Q114($0.52)($0.76)ViewN/AView Earnings Details
3/27/2014($0.62)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Dicerna Pharmaceuticals (NASDAQ:DRNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.85%
Institutional Ownership Percentage: 77.75%
Insider Trading History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2018James B WeissmanInsiderSell10,000$15.00$150,000.0019,800View SEC Filing  
4/20/2018James B WeissmanInsiderSell8,965$13.00$116,545.009,800View SEC Filing  
3/19/2018James B WeissmanInsiderSell1,035$13.00$13,455.0018,765View SEC Filing  
12/18/2017Bain Capital Life Sciences InvDirectorBuy285,000$7.00$1,995,000.00View SEC Filing  
11/16/2016Dennis LangerDirectorSell23,766$3.52$83,656.3243,595View SEC Filing  
11/15/2016Douglas FambroughCEOBuy33,100$3.71$122,801.00View SEC Filing  
5/12/2016James B WeissmanInsiderBuy5,000$3.29$16,450.0015,100View SEC Filing  
11/25/2014James E FlynnInsiderSell321,965$11.36$3,657,522.40View SEC Filing  
11/7/2014James E FlynnInsiderSell214,164$9.05$1,938,184.20View SEC Filing  
10/15/2014James E FlynnInsiderSell117,778$10.86$1,279,069.08View SEC Filing  
10/14/2014James E FlynnMajor ShareholderSell36,115$11.02$397,987.30View SEC Filing  
10/10/2014James E FlynnMajor ShareholderSell30,214$12.13$366,495.82View SEC Filing  
2/4/2014James E FlynnInsiderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
2/4/2014Stephen J HoffmanDirectorBuy200,000$15.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dicerna Pharmaceuticals (NASDAQ DRNA) News Headlines

Source:
DateHeadline
Dicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.79 MillionDicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.79 Million
www.americanbankingnews.com - May 22 at 2:16 AM
Zacks: Analysts Anticipate Dicerna Pharmaceuticals (DRNA) to Post -$0.46 Earnings Per ShareZacks: Analysts Anticipate Dicerna Pharmaceuticals (DRNA) to Post -$0.46 Earnings Per Share
www.americanbankingnews.com - May 20 at 9:06 PM
Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR International, and Nordson with Renewed Outlook — Fundamental Analysis, Calculating Forward MovementResearch Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR International, and Nordson with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - May 18 at 9:22 AM
Brokers Issue Forecasts for Dicerna Pharmaceuticals Q2 2018 Earnings (DRNA)Brokers Issue Forecasts for Dicerna Pharmaceuticals' Q2 2018 Earnings (DRNA)
www.americanbankingnews.com - May 18 at 7:38 AM
Dicerna Pharmaceuticals (DRNA) Given Consensus Recommendation of "Buy" by BrokeragesDicerna Pharmaceuticals (DRNA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 17 at 6:11 PM
FY2018 EPS Estimates for Dicerna Pharmaceuticals (DRNA) Reduced by B. RileyFY2018 EPS Estimates for Dicerna Pharmaceuticals (DRNA) Reduced by B. Riley
www.americanbankingnews.com - May 17 at 7:14 AM
BRIEF-Dicerna Pharmaceuticals Q1 Loss Per Share $0.30BRIEF-Dicerna Pharmaceuticals Q1 Loss Per Share $0.30
www.reuters.com - May 16 at 5:07 PM
HC Wainwright Reaffirms Hold Rating for Dicerna Pharmaceuticals (DRNA)HC Wainwright Reaffirms Hold Rating for Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - May 15 at 1:31 PM
Dicerna Pharmaceuticals (DRNA) CEO Douglas Fambrough on Q1 2018 Results - Earnings Call TranscriptDicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 9:06 AM
Edited Transcript of DRNA earnings conference call or presentation 14-May-18 8:30pm GMTEdited Transcript of DRNA earnings conference call or presentation 14-May-18 8:30pm GMT
finance.yahoo.com - May 15 at 9:06 AM
Dicerna Pharmaceuticals (DRNA) Posts  Earnings Results, Beats Estimates By $0.57 EPSDicerna Pharmaceuticals (DRNA) Posts Earnings Results, Beats Estimates By $0.57 EPS
www.americanbankingnews.com - May 15 at 8:28 AM
Dicerna Pharmaceuticals: 1Q Earnings SnapshotDicerna Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 14 at 5:01 PM
James B. Weissman Sells 10,000 Shares of Dicerna Pharmaceuticals (DRNA) StockJames B. Weissman Sells 10,000 Shares of Dicerna Pharmaceuticals (DRNA) Stock
www.americanbankingnews.com - May 11 at 10:27 PM
Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug ApprovalsDespite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals
seekingalpha.com - May 7 at 8:45 AM
Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018
finance.yahoo.com - May 7 at 8:45 AM
Dicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.75 MillionDicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.75 Million
www.americanbankingnews.com - May 5 at 3:54 AM
Dicerna Pharmaceuticals (DRNA) Raised to Buy at BidaskClubDicerna Pharmaceuticals (DRNA) Raised to Buy at BidaskClub
www.americanbankingnews.com - May 5 at 12:29 AM
-$0.30 Earnings Per Share Expected for Dicerna Pharmaceuticals (DRNA) This Quarter-$0.30 Earnings Per Share Expected for Dicerna Pharmaceuticals (DRNA) This Quarter
www.americanbankingnews.com - May 3 at 6:05 PM
Dicerna Pharmaceuticals (DRNA) Upgraded at ValuEngineDicerna Pharmaceuticals (DRNA) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 11:33 PM
Dicerna Pharmaceuticals (DRNA) Set to Announce Earnings on MondayDicerna Pharmaceuticals (DRNA) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 9:21 AM
Dicerna Pharmaceuticals (DRNA) Insider Sells $116,545.00 in StockDicerna Pharmaceuticals (DRNA) Insider Sells $116,545.00 in Stock
www.americanbankingnews.com - April 24 at 10:22 PM
Cowen Reiterates Buy Rating for Dicerna Pharmaceuticals (DRNA)Cowen Reiterates Buy Rating for Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - April 24 at 9:06 PM
Traders Purchase High Volume of Call Options on Dicerna Pharmaceuticals (DRNA)Traders Purchase High Volume of Call Options on Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - April 24 at 6:12 AM
Health Care Sector Update for 04/23/2018: DRNA,ALNY,HSIC,BHVN,AKRX,FMSHealth Care Sector Update for 04/23/2018: DRNA,ALNY,HSIC,BHVN,AKRX,FMS
www.nasdaq.com - April 23 at 4:54 PM
Does Dicernas Settlement Agreement With Alnylam Make It A Buy?Does Dicerna's Settlement Agreement With Alnylam Make It A Buy?
seekingalpha.com - April 23 at 8:36 AM
Dicerna Pharmaceuticals (DRNA) Receives Consensus Rating of "Hold" from AnalystsDicerna Pharmaceuticals (DRNA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 22 at 3:16 PM
UPDATE: Dicerna Pharmaceuticals (DRNA) PT Raised to $17 at Evercore ISI Amid SettlementUPDATE: Dicerna Pharmaceuticals (DRNA) PT Raised to $17 at Evercore ISI Amid Settlement
www.streetinsider.com - April 21 at 8:43 AM
Evercore ISI Reiterates "Outperform" Rating for Dicerna Pharmaceuticals (DRNA)Evercore ISI Reiterates "Outperform" Rating for Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - April 20 at 1:19 PM
Zacks: Brokerages Expect Dicerna Pharmaceuticals (DRNA) Will Announce Earnings of -$0.30 Per ShareZacks: Brokerages Expect Dicerna Pharmaceuticals (DRNA) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 16 at 9:25 AM
ValuEngine Lowers Dicerna Pharmaceuticals (DRNA) to SellValuEngine Lowers Dicerna Pharmaceuticals (DRNA) to Sell
www.americanbankingnews.com - April 14 at 2:31 PM
Dicerna Pharmaceuticals (DRNA) Raised to "Buy" at ValuEngineDicerna Pharmaceuticals (DRNA) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - April 12 at 11:18 AM
Dicerna Pharmaceuticals (DRNA) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowDicerna Pharmaceuticals (DRNA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:03 PM
Dicerna to Present at the HC Wainwright Global Life Sciences ConferenceDicerna to Present at the HC Wainwright Global Life Sciences Conference
www.businesswire.com - April 3 at 8:56 AM
Dicerna to Present at the H.C. Wainwright Global Life Sciences ConferenceDicerna to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 3 at 8:56 AM
Dicerna Pharmaceuticals (DRNA) Upgraded by ValuEngine to "Hold"Dicerna Pharmaceuticals (DRNA) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 1 at 10:20 PM
 Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $1.75 Million Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $1.75 Million
www.americanbankingnews.com - April 1 at 4:04 AM
Dicerna Pharmaceuticals (DRNA) Lifted to Hold at ValuEngineDicerna Pharmaceuticals (DRNA) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
Dicerna Pharmaceuticals (DRNA) Lowered to "Hold" at BidaskClubDicerna Pharmaceuticals (DRNA) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 9:27 AM
Equities Analysts Issue Forecasts for Dicerna Pharmaceuticals Incs FY2018 Earnings (DRNA)Equities Analysts Issue Forecasts for Dicerna Pharmaceuticals Inc's FY2018 Earnings (DRNA)
www.americanbankingnews.com - March 30 at 7:05 AM
Dicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Hold" from AnalystsDicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 5:56 PM
Dicerna Pharmaceuticals (DRNA) Coverage Initiated by Analysts at Evercore ISIDicerna Pharmaceuticals (DRNA) Coverage Initiated by Analysts at Evercore ISI
www.americanbankingnews.com - March 28 at 2:06 PM
Dicerna Pharmaceuticals (DRNA) Downgraded by BidaskClub to HoldDicerna Pharmaceuticals (DRNA) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - March 28 at 11:26 AM
B. Riley Initiates Coverage on Dicerna Pharmaceuticals (DRNA)B. Riley Initiates Coverage on Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - March 28 at 8:06 AM
Dicerna Pharmaceuticals (DRNA) Stock Rating Upgraded by ValuEngineDicerna Pharmaceuticals (DRNA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM
Dicerna Pharmaceuticals (DRNA) Lifted to "Strong-Buy" at BidaskClubDicerna Pharmaceuticals (DRNA) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 24 at 8:23 PM
H.C. Wainwright Downgrades Dicerna Pharmaceuticals (DRNA) to Neutral Citing ValuationH.C. Wainwright Downgrades Dicerna Pharmaceuticals (DRNA) to Neutral Citing Valuation
www.streetinsider.com - March 24 at 4:55 PM
Dicerna Pharmaceuticals (DRNA) Stock Rating Lowered by BidaskClubDicerna Pharmaceuticals (DRNA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 23 at 11:22 PM
HC Wainwright Lowers Dicerna Pharmaceuticals (DRNA) to NeutralHC Wainwright Lowers Dicerna Pharmaceuticals (DRNA) to Neutral
www.americanbankingnews.com - March 23 at 2:56 PM
Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - March 23 at 8:49 AM
21 Stocks Moving In Thursdays Pre-Market Session - Benzinga21 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - March 22 at 9:01 AM

SEC Filings

Dicerna Pharmaceuticals (NASDAQ:DRNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dicerna Pharmaceuticals (NASDAQ:DRNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dicerna Pharmaceuticals (NASDAQ DRNA) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.